SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-157554
Filing Date
2024-06-07
Accepted
2024-06-07 17:26:59
Documents
14
Period of Report
2024-06-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d839723d8k.htm   iXBRL 8-K 43036
2 EX-10.1 d839723dex101.htm EX-10.1 86233
  Complete submission text file 0001193125-24-157554.txt   273930

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fate-20240603.xsd EX-101.SCH 2876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20240603_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20240603_pre.xml EX-101.PRE 10829
18 EXTRACTED XBRL INSTANCE DOCUMENT d839723d8k_htm.xml XML 3577
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 241030771
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)